Health Net enoxaparin Coverage & Prior Auth

Coverage Criteria for Enoxaparin (Lovenox)

Initial Therapy

Covered when ALL of the following are met for initial approval:

Initial Approval - Documentation: Provider must submit documentation (office chart notes, lab results, or other clinical information) supporting that the member meets all approval criteria.

See indication subnodes.

Indications (pick any): Request is for prophylaxis or treatment of thrombosis/thromboembolism associated with one of the listed conditions (e.g., cancer, atrial fibrillation or prosthetic heart valve, unstable angina or myocardial infarction, major surgery orthopedic or non-orthopedic, restricted mobility from acute illness, critical illness/ICU, implanted vascular devices including central venous access or hemodialysis devices, short-term prophylaxis for transition to/from oral anticoagulation, or treatment of acute thrombosis/thromboembolism).

Includes conditions listed in policy Appendix D.

Product selection: If the request is for brand Lovenox, member must use generic enoxaparin unless contraindicated or clinically significant adverse effects are experienced.

Applies across indications; Medicaid/HIM typical approval duration 6 months.

Continuation Therapy

Covered for continuation when ALL of the following apply:

Continuation eligibility: Member is currently receiving the medication via the Centene benefit, or has previously met initial approval criteria, or is enrolled in a state/product with continuity-of-care regulations.

Continuation also requires that the member is responding positively to therapy.

Allowed continued indications: Continued use is limited to specified indications such as venous thrombosis prophylaxis or treatment in the presence of cancer, past history of failed anticoagulation on a non-LMWH agent, or other indications where bridging to warfarin is inappropriate or warfarin is contraindicated requiring extended anticoagulation.

LMWHs include enoxaparin and dalteparin; if branded Lovenox requested, generic enoxaparin required unless contraindicated.

Anticoagulation in Pregnancy (Ante‑ and Postpartum)

Anticoagulation in Pregnancy (off-label) — coverage requires ALL:

Pregnancy indications: Indication is one of the listed pregnancy-related thrombotic conditions (e.g., acute venous thrombosis during current pregnancy, prior venous thrombosis, prosthetic heart valve, current long-term vitamin K antagonist therapy, inherited thrombophilia, antiphospholipid antibody syndrome, severe ovarian hyperstimulation syndrome after assisted reproduction, cesarean section in current pregnancy requesting postpartum therapy, or other pregnancy indications listed in section I.A).

Member must be pregnant or < 6 months postpartum for postpartum requests; duration differs by product/line of business.

Product selection and duration: If request is for Lovenox, member must use generic enoxaparin unless contraindicated or clinically significant adverse effects are experienced.

Medicaid/HIM: antepartum to estimated delivery date and postpartum up to 6 months; Commercial: 6 months or duration of request, whichever is less.

Covered indications and dosing

Covered when meeting indication-specific criteria consistent with NCCN/CHEST guidance

Cancer-associated VTE: Use enoxaparin for anticoagulation in cancer-associated venous thromboembolic disease (including acute DVT, PE, catheter-related DVT, splanchnic vein thrombosis) when no contraindication to anticoagulation exists; enoxaparin is preferred in certain GI lesions and may be used after progression on other anticoagulants.

References NCCN compendium and guidelines

Perioperative and inpatient prophylaxis: Prophylactic dosing for adults with cancer or suspected cancer admitted for medical or surgical hospitalizations and for high-risk pre/postoperative dosing (e.g., abdominal/pelvic surgery); consider up to 4 weeks post-op for high-risk ambulatory patients.

References NCCN

Dosing regimens: Use indication-specific dosing: examples include DVT prophylaxis in medical/abdominal surgery: 40 mg SC once daily; knee replacement: 30 mg SC every 12 hours; hip replacement: 30 mg SC every 12 hours or 40 mg SC once daily; treatment dosing generally 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily.

See dosing appendix for full regimens

Requests for use of enoxaparin for non‑FDA approved indications that are not specifically addressed in this policy will be considered not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid), or unless coverage is supported by an evidence of coverage document.

Enoxaparin has specific contraindications and boxed warnings that must be reviewed before authorization. Contraindications include active major bleeding, a history of immune‑mediated heparin‑induced thrombocytopenia (HIT) within the past 100 days or presence of circulating HIT antibodies, and known hypersensitivity to enoxaparin (including pruritus, urticaria, anaphylactic/anaphylactoid reactions). The product labeling also notes hypersensitivity considerations to heparin and pork products and to benzyl alcohol in the multidose formulation. Additionally, the labeling contains a boxed warning for spinal/epidural hematomas.

Coverage for indications that are not FDA‑approved and are not described in this policy is excluded unless the provider submits adequate supporting documentation per the referenced off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) or other evidence of coverage demonstrating safety and efficacy.

Coverage criteria for enoxaparin are detailed throughout this policy and include initial approval, continuation, pregnancy‑related anticoagulation, and indication‑specific dosing consistent with cited NCCN/CHEST guidance. Providers must submit clinical documentation showing the member meets the applicable approval nodes (indication, dosing, and product selection), and requests for branded Lovenox require use of generic enoxaparin unless contraindicated or clinically justified. See the COVERAGE CRITERIA sections for specific scenarios (initial therapy, continuation, pregnancy, cancer‑associated VTE, perioperative prophylaxis, and dosing regimens).

Initial Therapy Requirements

Initial Therapy

Initial therapy requirements:

Initial Documentation Requirement: Provider must submit documentation supporting that the member meets approval criteria for a listed indication (office notes, labs, or other clinical information).

See indication nodes in policy.

Initial Indications: Indications include prophylaxis or treatment of thrombosis/thromboembolism for cancer, atrial fibrillation/prosthetic heart valve, unstable angina/MI, major surgery, restricted mobility due to acute illness, critical illness, implanted vascular devices, transition to/from oral anticoagulation, and other listed conditions.

Includes off-label adult and pediatric uses where specified.

Brand vs Generic: If branded Lovenox is requested, member must use generic enoxaparin unless contraindicated or clinically significant adverse effects occur.

Medicaid/HIM approval duration typically 6 months.

Continuation Therapy Requirements

Continuation Therapy

Continuation criteria for enoxaparin:

Continuation eligibility: Member is currently receiving medication via Centene benefit or previously met initial approval criteria, or is enrolled in a state/product with continuity-of-care regulations; member must be responding positively to therapy.

If branded Lovenox requested, generic enoxaparin required unless contraindicated.

Permitted continuation indications: Continued use is limited to indications including cancer-associated thrombosis, past failed anticoagulation on non-LMWH agents, or situations where bridging to warfarin is inappropriate or warfarin is contraindicated requiring extended therapy.

LMWHs include enoxaparin and dalteparin.

Continuation therapy

Continuation rules reference plan redirection language and duration policies.

Provider Actions and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required. Provider must submit a prior authorization request demonstrating the member meets the policy's approval criteria for enoxaparin (Lovenox) before coverage will be authorized.

Submit indication, dosing, and clinical justification for the requested duration and dose
If the request is for Lovenox brand product, document why generic enoxaparin is contraindicated or caused clinically significant adverse effects

Denial Risk

Non‑covered Indications Risk

Requests for indications that are not FDA‑approved or not specifically addressed in this policy may be denied unless the provider submits sufficient documentation of efficacy and safety according to the applicable off‑label use policies (e.g., CP.CPA.09 for commercial, HIM.PA.154 for HIX, CP.PMN.53 for Medicaid) or other evidence of coverage documents.

Provide literature, guidelines, or other clinical evidence supporting the off‑label use when applicable

Coding and Scoring

HCPCS CodesHCPCS

J1650

Injection, enoxaparin sodium, 10 mg

Khorana score threshold for ambulatory pancreatic cancer VTE prophylaxis

Khorana score threshold>= 2

PopulationAmbulatory adults with advanced unresectable or metastatic pancreatic cancer receiving/starting systemic therapy

Risk assessment useKhorana score used to identify intermediate or high risk for VTE

Step Therapy Considerations

Step	Requirement
1	Document the clinical reason for selecting enoxaparin (examples: cancer-associated venous thromboembolism, progression or new thrombosis while on prior therapeutic anticoagulation, or failure/intolerance of a prior anticoagulant).
2	If switching from or to an oral anticoagulant or other parenteral agent, provide documentation of prior anticoagulant therapy (agent, dose, dates) and the clinical justification per NCCN/CHEST guidance (e.g., progression on heparin, fondaparinux, warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban).
3	For cancer-associated VTE, indicate whether enoxaparin will be used as monotherapy or as part of a transition (administered for at least 5 days concurrently with warfarin until transition to warfarin monotherapy or to switching regimens when appropriate).
4	Specify setting and dosing regimen (inpatient vs outpatient; treatment or prophylactic dosing) consistent with policy dosing guidance (e.g., treatment 1 mg/kg SC every 12 hours or 1.5 mg/kg once daily; cancer maintenance 1 mg/kg once daily after first month; prophylaxis 40 mg SC once daily).

Quantity Limits and Formulations

Enoxaparin — available formulations

Prefilled syringe strengths30 mg/0.3 mL; 40 mg/0.4 mL

Graduated prefilled syringe strengths60 mg/0.6 mL; 80 mg; 100 mg/1 mL; 120 mg

Multiple-dose vial300 mg/3 mL vial

Site of Care and Administration

Note

Specify site of care — inpatient, outpatient, or home per NCCN

Specify the site of care on the prior authorization; enoxaparin is used in inpatient and outpatient settings and may be administered at home for ambulatory cancer patients per NCCN recommendations.

Acceptable settings include: home, office, infusion center, hospital outpatient

Background

Enoxaparin is a low molecular weight heparin (LMWH) anticoagulant used for prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and for certain acute coronary syndromes. Indications include DVT prophylaxis in surgical and medically ill patients, treatment of acute DVT with or without PE (often in conjunction with warfarin for transition), prophylaxis of ischemic complications in unstable angina/non‑Q‑wave MI with aspirin, and treatment of STEMI.

Definitions and Abbreviations

LMWH definition

DefinitionLow molecular weight heparin (LMWH) — enoxaparin, an anticoagulant used for prophylaxis and treatment of DVT and PE.

Indications referencedProphylaxis of DVT (which may lead to PE) in surgical and medically ill patients; treatment of acute DVT with or without PE; other thromboembolic indications.

Class notePreferred LMWH for certain cancer-associated venous thromboembolic disease per NCCN guidance.

DVT / PE

DefinitionDeep vein thrombosis and pulmonary embolism — thromboembolic conditions addressed by this policy.

ScopeIncludes acute DVT, catheter-related DVT, splanchnic vein thrombosis, and PE in cancer and non-cancer patients where indicated.

OpenPayer

Enoxaparin (Lovenox) Coverage Criteria